High Throughput Screening Against Pantothenate Synthetase Identifies Amide Inhibitors Against and

Overview

Journal In Silico Pharmacol

Date 2019 Jan 5

PMID 30607322

Citations 6

Authors

Sayantan Pradhan

Chittaranjan Sinha

Affiliations

Soon will be listed here.

Abstract

Abstract: Pantothenate is a crucial enzyme for the synthesis of coenzyme A and acyl carrier protein in and . It is indispensable for the growth and survival of these bacteria. Amides analogs are designed and have been used as inhibitors of pantothenate synthetase. Molecular docking approach has been used to design and predict the drug activity of molecule to the specific disease. In this work, more than hundred amides have been screened by Discovery Studio molecular docking programme to search best suitable molecule for the treatment of . Pharmacophore generation has been done to recognize the binding modes of inhibitors in the receptor active site. To observe the stability and flexibility of inhibitors molecular dynamics (MD) simulation has been done; Lipinski's rule of five protocols is followed to screen drug likeness and ADMET (absorption, distribution, metabolism, excretion and toxicity) filtration is also used to value toxicity. DFT computation of optimized geometry and derivation of MOs has been used to correlate the drug likeness. The small difference in energy between HOMO and LUMO may help to activate the drug in the protein environment quickly. 2-Hydroxy-5-[(E)-2-{4-[(prop-2-enamido)sulfonyl]phenyl}diazen-1-yl]benzoic acid (M1) shows best theoretical efficiency against (MTB) pantothenate synthetase and so does 2-hydroxy-5-[(E)-2-{4-[(2-phenylacetamido)sulfonyl]phenyl}diazen-1-yl]benzoic acid (M2) against pantothenate synthetase. These compounds also bind to Adenine-Thymine region of tuberculosis DNA.

Graphical Abstract:

Citing Articles

Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in : A computational approach.

Chouhan M, Tiwari P, Mishra R, Gupta S, Kumar M, Abdullah Almuqri E Front Pharmacol. 2024; 15:1403900.

PMID: 39135797 PMC: 11317409. DOI: 10.3389/fphar.2024.1403900.

Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis.

Khan M, Ali A, Rehman H, Khan S, Hammad H, Waseem M Sci Rep. 2024; 14(1):10904.

PMID: 38740859 PMC: 11091173. DOI: 10.1038/s41598-024-61752-6.

Inhibitors of pantothenate synthetase of - a medicinal chemist perspective.

Suresh A, Srinivasarao S, Khetmalis Y, Nizalapur S, Sankaranarayanan M, Sekhar K RSC Adv. 2022; 10(61):37098-37115.

PMID: 35521286 PMC: 9057165. DOI: 10.1039/d0ra07398a.

Identification of Putative Vaccine and Drug Targets against the Methicillin-Resistant by Reverse Vaccinology and Subtractive Genomics Approaches.

Naorem R, Pangabam B, Bora S, Goswami G, Barooah M, Hazarika D Molecules. 2022; 27(7).

PMID: 35408485 PMC: 9000511. DOI: 10.3390/molecules27072083.

Screening of Compounds for Anti-tuberculosis Activity, and and Evaluation of Potential Candidates.

Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y Front Microbiol. 2021; 12:658637.

PMID: 34276592 PMC: 8278749. DOI: 10.3389/fmicb.2021.658637.

References

Mortelmans K, Zeiger E . The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000; 455(1-2):29-60. DOI: 10.1016/s0027-5107(00)00064-6. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

von Delft F, Lewendon A, Dhanaraj V, Blundell T, ABELL C, Smith A . The crystal structure of E. coli pantothenate synthetase confirms it as a member of the cytidylyltransferase superfamily. Structure. 2001; 9(5):439-50. DOI: 10.1016/s0969-2126(01)00604-9. View

Lin J, Yamazaki M . Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2002; 42(1):59-98. DOI: 10.2165/00003088-200342010-00003. View

Wang S, Eisenberg D . Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexes with substrates and a reaction intermediate. Protein Sci. 2003; 12(5):1097-108. PMC: 2323879. DOI: 10.1110/ps.0241803. View

Chenna R, Sugawara H, Koike T, Lopez R, Gibson T, Higgins D . Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31(13):3497-500. PMC: 168907. DOI: 10.1093/nar/gkg500. View

Wu G, Robertson D, Brooks 3rd C, Vieth M . Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem. 2003; 24(13):1549-62. DOI: 10.1002/jcc.10306. View

Grassl S . Human placental brush-border membrane Na(+)-pantothenate cotransport. J Biol Chem. 1992; 267(32):22902-6. View

Hou T, Xia K, Zhang W, Xu X . ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. J Chem Inf Comput Sci. 2004; 44(1):266-75. DOI: 10.1021/ci034184n. View

10.

Bohm H . The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992; 6(1):61-78. DOI: 10.1007/BF00124387. View

11.

Uttamsingh V, Lu C, Miwa G, Gan L . Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005; 33(11):1723-8. DOI: 10.1124/dmd.105.005710. View

12.

Sanguinetti M, Tristani-Firouzi M . hERG potassium channels and cardiac arrhythmia. Nature. 2006; 440(7083):463-9. DOI: 10.1038/nature04710. View

13.

Overington J, Al-Lazikani B, Hopkins A . How many drug targets are there?. Nat Rev Drug Discov. 2006; 5(12):993-6. DOI: 10.1038/nrd2199. View

14.

White E, Southworth K, Ross L, Cooley S, Gill R, Sosa M . A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen. 2006; 12(1):100-5. DOI: 10.1177/1087057106296484. View

15.

Soga S, Shirai H, Kobori M, Hirayama N . Use of amino acid composition to predict ligand-binding sites. J Chem Inf Model. 2007; 47(2):400-6. DOI: 10.1021/ci6002202. View

16.

Yildiz I, Ertan T, Bolelli K, Temiz-Arpaci O, Yalcin I, Aki E . QSAR and pharmacophore analysis on amides against drug-resistant S. aureus. SAR QSAR Environ Res. 2008; 19(1-2):101-13. DOI: 10.1080/10629360701844159. View

17.

Hou T, Wang J . Structure-ADME relationship: still a long way to go?. Expert Opin Drug Metab Toxicol. 2008; 4(6):759-70. DOI: 10.1517/17425255.4.6.759. View

18.

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

19.

Bartzatt R, Cirillo S, Cirillo J . Sulfonamide agents for treatment of Staphylococcus MRSA and MSSA infections of the central nervous system. Cent Nerv Syst Agents Med Chem. 2010; 10(1):84-90. DOI: 10.2174/187152410790780109. View

20.

. The Sulfa Derivatives in the Treatment of Tuberculosis. Can Med Assoc J. 2010; 51(5):467. PMC: 1581917. View